Rita C. Peters

With some FDA inspections on hold, will the US drug supply maintain its quality standards?

Contract service organizations can offer biopharma companies early insight into dangers that may hinder a drug’s later development.

Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

Achieving effective manufacturing processes and sufficient capacity remains a top priority across a diversified biologic drug pipeline.

The promise of new therapies is tempered by the need for affordability, safety, and ethics.

With a positive employment market, some biopharma professionals explore options for career advancement.

Warning letters tell the tale of missteps by drug companies and offer a path to compliance for quality teams that monitor these enforcement actions.

Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.

FDA report says drug shortages are underappreciated and patients pay a price.